Get the app
US › Healthcare

Ovid Therapeutics Inc (OVID)

US · Healthcare · Biotechnology

$2.85+10.47%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$733,000
Revenue YoY
-88.3%
Net profit
$-15.0M
EPS
$-0.08
EPS estimate
$-0.10
Net margin
-2,047.6%

EPS came in at -0.08 against a street estimate of -0.10 — a beat of 20.0%.

Key statistics

Market cap
$503.9M
Forward P/E
1.8
P/B
2.40
Book value
$1.14
EPS (TTM)
$-0.22
52-week high
$3.10
52-week low
$1.18
50-day MA
$2.51
200-day MA
$2.38
Beta
0.24

Analyst view

Analysts rate Ovid Therapeutics Inc a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $6.40.

Shareholding

Insiders
6.72%
Institutions
80.32%

Largest institutional holders

FundStake
Jupiter Topco LLC10.62%
Eventide Asset Management, LLC6.05%
BlackRock Inc5.54%
RA Capital Management, LLC5.38%
Affinity Asset Advisors, LLC5.19%
State Street Corp4.05%
Vanguard Capital Management, LLC3.97%
ADAR1 Capital Management LLC3.80%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ovid Therapeutics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.